

# Kindstar Globalgene Technology, Inc. 康聖環球基因技術有限公司

(Incorporated in the Cayman Islands with limited liability) Stock Code: 9960

# 2023 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

Ē

# Contents

1	Board of Directors' Statement
2	1. About This Report
4	2. About Kindstar Global
9	3. Promoting Scientific Research Development
10	4. Quality of Service and Testing
19	5. Anti-Corruption and Building Integrity
22	6. Human Resources Management
26	7. Promoting Environmental Protection
32	8. Public Welfare and Harmonious Community
33	Appendix 1: Sustainable development information summary
36	Content Index



### **Board of Directors' Statement**

The Board of Directors (the "**Board**") of Kindstar Globalgene Technology, Inc. (the "**Company**") and its subsidiaries ("**Kindstar Global**", the "**Group**" or "**we**") is the highest responsible and decision-making institution for environmental, social and governance ("**ESG**") matters and has ultimate responsibility for the Group's ESG strategies and ESG report ("**this Report**"), and monitors ESG related matters that may affect the Group's business or operation, shareholder and other stakeholders<sup>1</sup>. The Environmental, Social and Governance Committee ("**ESG Committee**") under the Board is responsible for identifying and assessing ESG risks associated with the Group, ensuring that the Group has put in place appropriate and effective ESG risk management and internal control systems, and reporting to and reviewing the progress made in achieving the relevant ESG objectives. For details, please refer to "ESG Strategies and Management".

The Group values the suggestions and views of various stakeholders and ensures adequate channels for communication with key stakeholders to discuss and identify the Group's important ESG issues and possible ESG risks, and to continuously improve its ESG related strategies and policy systems. The Board has considered the major ESG issues of the year and has adopted proposals to adjust the importance of each ESG issue, ensuring the timeliness and reasonableness of the major issues matrix. For details, please refer to "Stakeholder Engagement".

The Group has put in place a management system of ESG objectives relating to carbon emissions, pollutant emissions, energy consumption, water resources management and other indicators, and the Board reviews the progress of the objectives on an annual basis and reviews any necessary adjustments or improvements to ensure that the Group continues to make progress in achieving its ESG objectives. For details, please refer to "Green Operations Management".

The Board and all Directors is committed to ensuring that the contents of this Report are free of any misrepresentation, misleading statements or material omissions, and accept responsibility for the truthfulness, accuracy and completeness of the report. This Report provides detailed information on the progress and effectiveness of the Group's ESG work in 2023 and undertakes to strive to ensure that all data presented in this Report are accurate and reliable and managed through the establishment of internal control and formal review procedures. This Report was confirmed and approved by the Board of Directors on 27 March 2024.

<sup>1</sup> Stakeholders, refer to groups and individuals who have a significant impact on or will be affected by an enterprise's business, including internal board of directors, management, administrative staff and general employees, as well as external shareholders, business partners, customers, government and regulatory agencies, banks and investors and community groups.

### 1. About this Report

#### **1.1. Introduction of this Report**

This Report is the third ESG report published by the Group. This Report allows stakeholders to have a better understanding of the Group's work on ESG by summarizing the Group's principle, concept and key performance indicators ("**KPI**") on environmental and social aspects.

#### **1.2. Scope of this Report**

This Report covers the overall sustainable development practiced by Kindstar Global from January 1, 2023 to December 31, 2023 (the "**Reporting Period**"). The scope of this Report covers the main business of the Group, with social aspects consistent with the Group's annual report and environmental aspect covering the Group's Wuhan headquarter and major subsidiaries in Shanghai, Beijing, Tianjin, Sichuan, Xinjiang and Wuhan with business operations, all operating subsidiaries with business operation companies in the People's Republic of China (the "**PRC**" or "**China**") within the scope of the Group's audited consolidated statements, including:

- Wuhan Kindstar Medical Laboratory Co., Ltd.
- Wuhan Kindstar Zhenyuan Medical Laboratory Co., Ltd.
- Wuhan Kindstar Qiyuan Medical Laboratory Co., Ltd.
- Wuhan Kindstar Zeyuan Medical Laboratory Co., Ltd.
- Beijing Hightrust Medical Laboratory Co., Ltd.
- Tianjin Kindstar Medical Laboratory Co., Ltd.
- Xinjiang Kindstar Medical Laboratory Co., Ltd.
- Wuhan Kindstar Biotechnology Co., Ltd.
- Wuhan HumanCell Biotechnology Co., Ltd.
- Wuhan Xinuo Medical Laboratory Co., Ltd.
- Shanghai SimpleGene Medical Laboratory Co., Ltd.
- Shanghai Xinuo Medical Laboratory Co., Ltd.
- Shanghai SinoPath Medical Laboratory Co., Ltd.
- Wuhan Xinuo Medical Biotechnology Co., Ltd.
- Wuhan Yijianyun Information Technology Co., Ltd.
- Chengdu Wenjiang Kangshengyou Medical Internet Hospital Co., Ltd.
- Wuhan Haixi Life Science Technology Co., Ltd.
- Wuhan Haixi Biological Technology Co., Ltd.
- Sichuan Huaxi Kindstar Medical Co., Ltd.
- Chengdu Shengyuan Medical Laboratory Co., Ltd.
- Guangzhou SouthMed Kindstar Biotechnology Co., Ltd.
- Hunan Kindstar Medical Laboratory Co., Ltd.
- Kindstar Global (Wuhan) Medical Esoteric Technology Co., Ltd.
- Wuhan Kindstar Kindan Medical Laboratory Co., Ltd.
- Wuhan Kindstar Qinghe Medical Laboratory Co., Ltd.
- Kindstar Sequenon Biotechnology (Wuhan) Co., Ltd.

#### **1.3. Reporting Standards**

This Report is prepared in accordance with the mandatory disclosure requirements and "Comply or Explain" provisions of the Appendix C2 – "Environmental, Social and Governance Reporting Guide" ("**the Guide**") of the Rules Governing the Listing of Securities of the Stock Exchange of Hong Kong Limited. This Report is prepared based on the following four reporting principles:

Materiality: This Report has identified material ESG topics and disclosed the process to identify and the criteria for the selection of material ESG topics and the process and results of stakeholder engagement.

Consistency: The statistical methodologies used for information disclosure in this Report are consistent with last year's ESG report. Any changes will be clearly stated in this Report.

Quantitative: The statistical standards, methodologies, assumptions, calculation tools and source of conversion factors used, for the reporting of KPI and related data, are stated in this Report.

Balance: This Report provides an unbiased picture of the Group's performance and avoids selections, omissions, or presentation formats that may inappropriately influence a decision or judgment by the report reader.

#### 1.4. Reporting Language

This report is published in both Traditional Chinese and English. In case of any discrepancy, the Traditional Chinese version shall prevail.

### 2. About Kindstar Global

Kindstar Global is a large-scale group providing high-end medical specialty esoteric testing services in China, providing systematic, comprehensive and advanced specialty testing services, our service network has covered 31 provinces/municipalities directly under the central government and more than 600 cities in China. We have cooperated with more than 4,000 hospitals, including more than thousands tertiary hospitals providing more than 3,800 advanced and accurate diagnostic tests in such field as blood, tumor, genetics, cardiovascular and cerebrovascular diseases, infectious diseases, and autoimmune diseases, as well as in internal medicine, surgery, gynecology, pediatrics and other specialties.

The Group's aim is "Patients' interest is our priority and doctors' need come first" (病人利益至上、醫生需求第一). The Group is committed to advancing the specialty esoteric technologies and services in China and promoting the development and improvement of specialty diagnosis and treatment and personalized medicine in China. We have introduced and developed the world's advanced technologies and specialty testing methods, as well as strictly complying with international norms, standards and industry guidelines.

Kindstar Global has built internationally-advanced laboratory facilities of 50,000 square meters for clinical testing, scientific research cooperation and applied R&D in Beijing, Shanghai, Wuhan, Xinjiang, Tianjin and Sichuan. We boast a dozen of specialized laboratories, including a high-resolution flow cytometry (FCM) testing platform, a PCR (real-time Polymerase chain reaction) platform, a gene chip platform (Affymetrix), a liquid chip platform (Luminex), a mass spectrometry platform (Sequenom), a digital gene platform (NanoString), a sequencing platform, a cytogenetic platform (chromosome karyotype analysis, FISH, etc.), a mass spectrometry platform, a clinical pathology platform, a clinical immune platform, and a clinical chemistry platform. Through cooperating with the world's top medical technology institutions and large pharmaceutical companies, we provide medical research, drug testing and translational medicine research services for clinicians all over China.

### 2.1. Honours of the Group

Date	Award Name	Award Winning Unit	Awarding Unit
February 2023	2023 "AAA" Grade Credit Enterprise	Wuhan Kindstar Medical Laboratory Co., Ltd,	China Bidding Enterprise Credit Evaluation and Publicity Platform
March 2023 March 2023	2022- 2023 Excellent High-tech Enterprise 2023 "AAA" Grade Credit Enterprise	Wuhan Kindstar Medical Laboratory Co., Ltd, Wuhan Kindstar Zhenyuan Medical Laboratory Co., Ltd,	Wuhan High-tech Industry Association China Bidding Enterprise Credit Evaluation and Publicity Platform
September 2023	2023 "AAA" Grade Credit Enterprise	Ltu, Shanghai SinoPath Medical Laboratory Co., Ltd,	China Bidding Enterprise Credit Evaluation and Publicity Platform
October 2023	2023 Optics Valley Gazelle Enterprise	Wuhan Haixi Biological Technology Co., Ltd,	Science and Technology Innovation and New Economic Development Bureau
November 2023	High-tech Enterprises	Tianjin Kindstar Medical Laboratory Co., Ltd,	Tianjin Science and Technology Bureau
November 2023	High-tech Enterprises	Beijing Hightrust Medical Laboratory Co., Ltd,	National High-tech Enterprise Identification Management Leading Group
December 2023	ESEV Emerging Enterprise of the Year Award – 2023 Emerging Enterprise	Wuhan Kindstar Biotechnology Co., Ltd,	Hubei Extracellular Sac Association

#### 2.2. ESG Strategies and Management

Kindstar Global has been continuously working on sustainable development. In 2021, the Group established the ESG Committee and Environmental, Social and Governance Working Group ("**ESG Working Group**") and have clearly listed the responsibilities of the Board and different units.

#### The Board

The Board is the highest authority in the decision-making of the Group's ESG governance. The Board mastering the Group's ESG information through the ESG Committee and the ESG Working Group, the Board is responsible for developing management approach and strategies for ESG issues, including materiality assessment, prioritizing and managing important ESG issues and reviewing the progress of ESG-related targets, etc.

#### **ESG Committee**

Under the leadership of the Group's Chief Financial Officer, the ESG Committee comprises the heads of the Administration Department, Finance Department, Legal Department, Human Resources Department and Investor Relations Department. The ESG Committee is responsible for formulating and reviewing ESG strategies and management methods, monitoring ESG issues and risks; communicating with other committees and the ESG Working Groups, coordinating the development of ESG work and regularly approving and reviewing the objectives and key measures.

#### **ESG Working Group**

The ESG Working Group is composed of all subsidiaries and divisions of the Group. The ESG Working Group is responsible for formulating and implementing ESG-related policies and procedures, monitoring and tracking the progress of ESG objectives and providing feedback to the ESG Committee.

#### 2.3. Stakeholder Engagement

The Group attaches high importance to communication and exchange with stakeholders. To facilitate effective and long-term communication with stakeholders, we identify stakeholders and establish different communication channels to fully understand their expectations and requirements. The Group will actively respond to the views of stakeholders to push forward sustainable development in the Group.

Major Stakeholders	Expectations and Requirements	Main Communication Channels
Shareholders and Investors	Operational compliance Return on investment	The general meetings of the
	Protection of shareholders' rights and	management teams; Corporate communications, such as
	interests	shareholder letters/circulars and
	Accuracy and timeliness of information	meeting notices;
	disclosure	Annual general meeting and general
		meetings of the shareholders
Regulatory Authorities	Operational compliance	Daily management;
	Ensure product quality and safety	Work meetings;
	Promote economic development	Compliance reports;
	Promote healthcare development	Regular monitoring and checking
Customers	Ensure product quality and safety	Customer satisfaction surveys and
	Ensure high quality and efficient	opinion forms;
	services	Comprehensive customer complaint
	Protection of customers' privacy	handling mechanism;
	Provision of professional esoteric	Online service platform; Hotlines;
	testing services	Website and emails of the Group;
		Customer service centers
Employees	Remuneration and benefits	Employee opinion survey;
1	Career development	Internal communication channels;
	Safe working environment	Job performance and assessment;
	Vocational training	Conference interviews;
	Humanistic care	Trainings;
		Employee activities;
		Seminars/Workshops/Talks
Business Partners/Suppliers	Integrity and mutual benefit	Meetings;
	Supply chain management	Supplier evaluation systems;
		On-site inspections;
		Meetings;
		Strategic partnership programme

Major Stakeholders	Expectations and Requirements	Main Communication Channels
Higher Education Institutions and Research Institutions	Innovative scientific research Promote healthcare development through cooperation Nurturing industry talents	Scientific research base meetings; Exchange activities; Participation in summits; Industry seminars
Community/Environment/ Non-governmental Organizations	Employment opportunities Effective use of resources Support community development Reduce pollutant emissions	Conducting charity activities; Donations; Volunteer activities/Environmental activities; Seminars/Workshops/Talks
Media	Accurate, transparent and efficient	Press conferences; Visits of senior management; Performance Reports

#### 2.4. Materiality Assessment

The Group discloses the process and guidelines for identifying material ESG issues of Kindstar Global in accordance with the materiality reporting principles. During the Reporting Period, there were no significant changes in the business operations of Kindstar Global, and the impact of the Group on stakeholders and vice versa. Therefore, in the Reporting Period, based on the results of the materiality assessment in 2021, the management team reviewed and summarized the results of the materiality assessment for the Reporting Period, the results were confirmed by the Board. The results of the materiality assessment of the Reporting Period are as follows:

High Importance	Medium Importance	Low Importance
<ul> <li>Product quality and safety</li> <li>Safe disposal of medical waste</li> </ul>	<ul> <li>Compliance operation</li> <li>Water resources use</li> <li>Employee welfare and rights</li> <li>High quality development</li> <li>Customer service and privacy protection</li> <li>Anti-money laundering and anticorruption</li> <li>Complaint handling</li> </ul>	<ul> <li>Employee career development</li> <li>Workplace safety and health</li> <li>Corporate culture</li> <li>Intellectual property right</li> <li>Greenhouse gas emission</li> <li>Energy use</li> <li>Responsible supply chain</li> <li>Community participation</li> <li>Social welfare activities</li> </ul>

### 3. Promoting Scientific Research Development

In the Reporting Period, the Group's fruitful scientific research achievements are attributed to years of innovation and R&D, cooperation and promotion. "Technology is the core competitiveness of an enterprise, and technological progress leads to technological development which drives an enterprise forward" (技術是企業的核心競爭力,科技進步 引領技術發展,技術發展帶動企業前進) is the corporate culture of Kindstar Global, and it is also our original intention to promote scientific research and development all the way through. In the Reporting Period, we have obtained success in several areas of testing technology, and have taken a step forward to promote systematic, comprehensive and advanced testing technology.

During the reporting period, we added 186 new research and development detection items, including 75 items related to molecular biology detection technology, 32 items related to flow cytometry detection technology, 42 items related to cytogenetic detection technology, 19 items related to pathological detection technology, and 18 items related to clinical detection. In 2023, the Group increased its focus on collaborative research and development across technology platforms, such as flow separation (**"FACS**") combined with fluorescence in situ hybridization (**"FISH**") detection. The Company's new product MicroLym-ALL gene mutation detection has been widely recognized in clinical practice, helping patients benefit from diagnosis, treatment, prognosis, medication, etc. The establishment and verification of AL Panel for full-spectrum flow immunotyping screening for acute leukemia have been recognized by the European Society for Clinical Cell Analysis (ESCCA) and the International Society for Clinical Flow Cytometry (ICCS).

#### Patent Management System

The Group strictly abides by the requirements of the Patent Law of the People's Republic of China 《中華人民共和國 國專利法》, the Implementation Regulations for the Patent Law of the People's Republic of China 《中華人民共和國 專利法實施細則》), the Trademark Law of the People's Republic of China 《中華人民共和國商標法》) etc., and have established the Intellectual Property Application Procedures 《知識產權申請流程》) and the Incentives for Researchers' R&D Achievements, Patent Applications and Publication of Professional Literature 《研究人員研發成果、專利申請及 專業文獻發表的獎勵辦法》). To protect the rights and interests of the Group, we register intellectual property rights for all patents and trademarks and provide three methods to facilitate employees to apply for them, including online application, self-application and entrusted application. We have also arranged specific people to be responsible for assisting employees of different departments in applying for intellectual property rights. To encourage and stimulate the creativity of our staff, R&D staff are entitled to a bonus payment, job promotion or salary adjustment.

During the Reporting Period, the Group obtained a total of 37 patents and published 1 scientific article.

### 4. Quality of Service and Testing

Kindstar Global upholds the principle of "Quality is Life" (質量是生命), which is the way we take care of the needs of our clients, patients and hospitals to provide the highest quality testing and specialty esoteric testing services. Our dedication and pursuit of quality are what drive us forward. We carry out quality management throughout our business, from procurement of materials to testing services, from customer medical consultation to the issuance of test reports, and we provide high-quality services to our customers in a professional and compliant manner at every step.

#### 4.1. Strict Control on the Quality of Test

Kindstar Global is committed to providing the best testing quality and focusing on the development of testing quality. Over the years, we have obtained several testing certificates for our testing work, such as the ISO 15189:2012 Medical Laboratories - Requirements for Quality and Competence, Certificate of Technical Acceptance of Clinical Gene Amplification Test Laboratory, and Medical Device Business License. We have developed various sample management, testing management and review documents, such as the Quality Manual 《質量手冊》, Pre-examination Procedure 《檢驗前程序》, Logistics Manual 《物流手冊》, Specimen Management Procedure (《標本管理程序》), Results Reporting Management Procedure (《結果報告程序》), Test Quality Assurance Procedures (《檢驗工作質量保證程序》), Procedure for the Evaluation of Test Procedure (《檢驗 程序的評審程序》), Comparison Management Procedure 《比對管理程序》), Internal Audit Procedure 《內部審核程 序》), Management Review Management Procedure 《管理評審管理程序》), Preventive Action Control Procedure 《預防措施控制程序》), Corrective Action Control Procedure《糾正措施控制程序》) and Equipment Management Procedure《設施管理程序》) etc. The Group strictly complies with the Law of the People's Republic of China on the Protection of Consumer Rights and Interests《中華人民共和國消費者權益保護法》) and the Law of the People's Republic of China on the Quality of Products《中華人民共和國產品質量法》. Our quality management covered every area of our business, from material procurement, customer testing requirements, equipment management, and pre-examination preparation, etc. We carry out every step of quality work precisely to provide the best quality service. The main business of the Group does not involve product or service recall.

In terms of procurement, for any new purchasing of laboratory supplies, a preliminary review of the goods is a compulsory step to be carried out by the warehouse manager, and inspection of the quality of goods will then be conducted by the use of the unit. If the goods do not meet the quality requirements, we will notify the purchasing specialist to apply for the return, exchange or claim of the goods.

To provide appropriate and accurate testing services, we provide our clients with pre-examination medical consultation. The consultation will be provided by clinicians to advise clients on the appropriate medical tests. We will prepare the Guide to General Practice Test Items 《全科檢驗項目指南》) to our clients, to let them thoroughly understand about the preparation, procedures and storage requirements for samples before and after sampling.

To ensure the quality of service for customers and to reduce errors, we have established a series of sampling and management procedures. We sort and label sample tubes according to the requirements for each test and verify client and test information. After sampling, the tubes are stored and registered. Each sample tube is accompanied by a unique barcode label to distinguish the sample data. The sample tubes are properly stored in appropriate bags and boxes and refrigerated as required and shipped to the receiving units.

Quality control of test work is one of our top priorities. We carefully monitor the quality of every test and review the suitability of the testing items, and determine whether adjustments to the content have to be made. Staff with the authorization to use the testing machinery have received appropriate training, we will also carry out regular maintenance and repair of equipment to ensure testing machines are in the best condition for operation. To enhance the credibility of test results, we have established inter-laboratory comparison activities, where two or more laboratories perform the same test on sample and the results are reviewed to conduct comparability studies.

With the upgrading of various testing technologies, testing methods are changing with each passing day, we regularly review our testing methods to ensure that they meet the quality requirements and prevent any occurrence of non-compliance. Moreover, other than taking into account the recommendations of our clients, healthcare providers and the latest academic advances, we also review the equipment and reagents used for sampling, sample storage, transportation and testing, etc. We analyze and correct any non-compliant issues, as well as review if there is a need for updates and changes.

We will report the test results to our clients in written or electronic reports or via phone calls. The contents will be verified, approved and released by an auditor with appropriate professional qualifications. The content of the report will contain the test label, the company logo and sampling information, etc.

Test:

# Quality Management

Pre-testing:

Documents:

Quality Manual; Pre-examination Procedure; Logistics Manual; Specimen Management Procedure

#### Quality Management Measures:

- Quality management of purchasing materials
- Preparation of "Guide to General Practice Test Items"
- Sample management

#### Quality Management Documents:

Quality Manual; Test Quality Assurance Procedure; Procedure for the Evaluation of Test Procedure; Preventive Action Control Procedure; Corrective Action Control Procedure; Equipment Management

#### Quality Management Measures:

Procedure

- Equipment management and maintenance
- Laboratory comparison testing
- Review of the suitability of the test content
- Adjustment of the test content when needed

#### Quality Management Documents: *Quality Manual;*

**Post-test:** 

Results Reporting Management Procedure; Comparison Management Procedure; Internal Audit Procedure; Management Review Management Procedure

#### Quality Management Measures:

- Regular review of testing procedure
- Submission of reports to customers through various channels
- Specification of report content style

During the Reporting Period, the Group accredited several testing quality certifications and was recognized by various authorities.

- Wuhan Kindstar Medical Laboratory Co., Ltd passed the evaluation of "Report on the Results of the Preliminary Research Activities for High-throughput Sequencing of National Lower Respiratory Tract Infection Metagenome (DNA and RNA)" and "GB/T 9001-2016/ISO9001:2015 Quality Management System Certification";
- Wuhan Kindstar Medical Laboratory Co., Ltd, Shanghai SimpleGene Medical Laboratory Co., Ltd, Sichuan Huaxi Kindstar Medical Laboratory Co., Ltd and Beijing Hightrust Medical Laboratory Co., Ltd passed the ISO15189 Medical Laboratory Quality and Competence Accreditation Guidelines;
- The monkeypox virus nucleic acid test kit and nine hematological tumor diagnostic kits developed by Wuhan Haixi Biological Technology Co., Ltd include: lymphoma gene mutation test, myeloid hematological disease gene mutation test, human whole exon test, immune repertoire TCR gene rearrangement test, immune repertoire IG gene rearrangement test, BCR-ABL1 fusion gene qualitative test, PML-RARA fusion gene qualitative test, and RUNX1-RUNX1TA fusion gene qualitative assay and human JAK2 gene V617F mutation assay obtained EU CE certification.

A MARKAN	CERTIFICATE
FRM	质量管理体系认证证书
	证书编号: 00221028552R0L
	兹证明
	武汉康圣达医学检验所有限公司
	统一社会信用代码: 914701007518253618 住所: 浙出省武汉市东湖特技术开发区高新大道 666 号克谷生物战生的利利因 12-1
	株 认该地址:潮北省式汉市东浦阳技术开展商所大道 666 号元答生物域生物创新因 102-1 練
and the second second	管理体系符合
	GB/T 19001-2016/ISO 9001:2015
A AN	
	概論的能用
	医学检验服务、病理诊断服务、临床试验服务
	(在这分型关节整定发行这次管察管理系统;实际型图444,444,444,444,444,444,444,444,444,44
	间,争克监督学校的《确认证书》用以证实生证书的作取者此性。)
200	生放日期: 2021年12月27日 一月上午, 行政期登: 2024年12月26日
- <u>I©Net</u> -	
AA 0043894	方面結定X.後来回 (management and contraction and May: 15:0年為日20世紀2014/1000007 Address Charlenge and Madden Madaen Madaen Madaen (Merjing P.R. Chara(18046)

Wuhan Kindstar Medical Laboratory Co., Ltd obtained 《GB/T 19001-2016/ISO 9001:2015 Quality Management System Certificate》



ISO15189:2012 Medical Laboratories – Requirements for Quality and Competence (CNAS-CL02 "Accreditation Criteria for the Quality and Competence of Medical Laboratories" requirements)


#### 4.2. High Quality Customer Service

Kindstar Global understands that customer feedback can further push our business and quality development, therefore we have established several procedures and channels to receive feedbacks. Complaint Handling Management Procedure (《投訴處理程序》), Procedure for Satisfaction Monitoring and Abnormal Feedback Handling (《客戶滿意度監測處理程序》), Medical Consulting Control Procedure (《醫療諮詢控制程序》), and Management Procedure for Revocation, Addition, Trial and Change Test Programs (《撤銷、增加、試做、更改檢 驗項目管理程序》) have been established to better regulate our customer services and handle feedbacks.

To provide the most suitable medical consulting services to our clients, and to provide the most appropriate selection of tests, interpretation results and consulting services for further testing, we have formed a medical consulting team to understand the needs of our clients and provide the most appropriate services. Clients also have the right to revoke, add, try, change and suspend their tests. The consulting team is responsible for explaining the content of the results to clients and to follow up with further issues.

Every year, we develop the Annual Customer Satisfaction Survey 《年度客戶滿意度調查計劃》 to collect customers' opinions. The survey is composed of sample collection, consultation and reporting, etc. After we summarize all the data, we will produce the Customer Complaint Analysis Report 《客戶投訴分析報告》) to analyze and summarize the customer complaints of the Reporting Period, compare with the complaint figures of previous years and propose improvements. We established multiple customer communication channels, including an online customer service hotline, official WeChat, Weibo, etc.

We have established a customer complaint procedure to ensure customer complaints can be properly resolved. If we receive a complaint from any customers, the quality department of the Group (the "Quality Department") will review the complaint information for preliminary investigation and take corresponding response measures to the complaint content. The Quality Department will communicate with relevant departments to find out the cause of the problem and reply to the customer according to the company's procedure document. In general, after the relevant departments receive an inquiry from the Quality Department, they have to verbally reply to the Quality Department within 3 hours, followed by sending the investigation result to the Quality Department within 2 working days, and finally, the Quality Department will reply to the customer. After the complaint is handled, the Quality Department will also contact the complainant to collect the complainant's opinion and prepare an Abnormal Feedback Processing Record Form 《異常反饋處理記錄表》) to record the investigation results and corrective measures. The Group also conducts regular online meetings and provides professional training to relevant personnel to reflect on and improve problem-handling methods. During the Reporting Period, we received a total of 7 complaints and all of them have been handled properly.



Customer complaint handling process

The Quality Department will perform professionally in handling and improving complaints, communicating with customers, building trust, trying to avoid misunderstandings with customers, and reducing the number of complaints. We will also analyze the core problems according to the content of the complaint information and regularly review and improve the procedures. Throughout the communication process with customers, we maintain honesty and will not perform any act of deception and defraud.

#### 4.3. Safeguarding Information Security

The Group strictly complies with the Law of the People's Republic of China on Guarding State Secrets 《中華人 民共和國保密法》, Implement Measures for Law of the People's Republic of China Law on Guarding Secrets 《中 華人民共和國保密法實施辦法》) and other regulations. We have formulated an Information Management System and Specification (《信息管理制度與規範》), Access Control Management Procedures 《訪問控制管理程序》) and Information Exchange Management Procedures 《信息交流管理程序》) to manage matters related to network, terminal, user and device and information security.

We regularly perform security level protection and risk assessment work for our information security, install antivirus programs, patch upgrade and other systems to computers, networks and terminals and other devices and update them regularly. To protect our data and systems, we will develop data backup plans and adopt appropriate methods to restore different types of data.

To ensure that the information released by the Group is authoritative, timely and accurate, we require all information to be reviewed in advance before being released to the public. The review process is first conducted internally and then followed by the review of the management team. Any information publisher is required to fill in the Information Release Approval Form (《信息發布審批表》) and Information Release Confidentiality Review Registration Form (《信息發布保密審查登記表》) to record information-related data. We will also arrange for professionals to regularly review the information system and correct any problematic information.

The Group has established policies to protect personal data. Employees are required to comply with the Kindstar Global's Customer Information Management Policies 《康聖環球客戶信息管理制度》) in handling customers' data, and strictly manage the processing of each personal data. Personal information should be processed at specific modules, and the processing unit and information department should verify the security of the data processing process. Sales personnel have to regularly update the information of the customers, if the customer has ended cooperation with the Group, the customer's information will be deleted.

During the Reporting Period, Kindstar Global did not violate any laws and regulations on consumer protection and privacy, nor violate any laws and regulations related to advertising and labelling.

During the Reporting Period, the information security management activities of medical testing services, diagnostic pathology services and clinical trial services testing of Wuhan Kindstar Medical Laboratory Co., Ltd has obtained the 《GB/T22080-2016/ISO/IEC 27001:2013 Information Security Management System Certification》. In addition, its production network has also obtained the 《National Information System Security Level Protection Level 2 Record》 issued by the Ministry of Public Security of the PRC, affirming the reliability and security of our system in terms of physical security, network security, data security, management system, personnel management, and system operation and maintenance management.

ABLA	CERTIFICATE
<b>BRM</b>	Information Security Management System Certificate
N N	Certificate Number:002221S0128R0L
1	CQM hereby certifies that
	Wuhan Kindstar Diagnostics Co.,Ltd
X	Lindia Social Credit Leordine 94/20100731233141 Dominik Bridling D21, Washing Lindi Washing Tu, Yugan Yang, Washing Zi, Yuga Yang, Yugan Y
	the management system conform to
2A	GB/T 22080-2016/ISO/IEC 27001:2013
L Y	This certificate is valid to the following scope:
X	Information security management activities related to medical inspection services, pathological diagnosis services and clinical trial services laboratory testing Information Security Applicability Statement A/0
A	The television of this configure on the hypoth in two ways given as whether (FOOL To confidure chally of the confidure on the detailed by Confidence Constrained on a confidence 1.
Y.	U: We Drag Issued on: 2022-04-07 Expires on: 2025-04-06
- <u>IQNet</u> -	
AA 0059235	方面株定认证書面 Gene Suur Hank Certricities Stear NML:22月用道区用光路339 (100068) Advention(13.2.mg)gung Baskylaidan District_Beijing/R. Chira(100068) Halp/Wave.com.com.com

#### 4.4. Standardize Procurement Management

The Group pays attention to the sustainable development of the supply chain. To manage the development of the supply chain more effectively, Kindstar Global has formulated the Procurement Management System (《採 購管理制度》). The purchasing department of the Group (the "**Purchasing Department**") is responsible for purchasing. Each department is required to submit a purchasing list at the beginning of each month for review by the department head and then submit it to the Purchasing Department. Based on the price ranges of the purchasing items, the approval of the purchasing request will be approved by different levels of authority to ensure the right choice can be made. Suppliers are selected from the Qualified Suppliers List 《合格供應商名錄》) and at least three suppliers are selected for price comparison. The Purchasing Department will regularly identify new suppliers and conduct basic background checking, collect information such as business licenses, tax certificates, reagents or medical device registration certificates, or request samples for trial testing or onsite examination, and then compile them into the Qualified Supplier List 《合格供應商名錄》).

The Group evaluates our suppliers at least once a year, and we perform evaluations according to the type of supplier and on different items such as qualification, quality assurance capability, service and reputation, and technical support capability. We will also consider whether the supplier has relevant quality qualifications, i.e. ISO9000 quality or CNAS laboratory accreditation, and will also evaluate the supplier's ability to meet our requirements.

The Group supports sustainable supply chain development and we will give priority to environmental friendly products. Kindstar Global highly values both integrity and honesty, we monitor every detail of the supply chain. We request our suppliers to sign the Letter of Honesty and Integrity Commitment by Suppliers 《供應服務商 廉潔誠信承諾書》) to ensure that the entire procurement process is clean and lawful. Suppliers are expected to comply with environment, labour, health and safety-related regulatory requirements. If the behaviour of the supplier violates Group's policy, we will terminate the cooperation with the supplier until the situation has improved.


During the Reporting Period, we had 105 suppliers providing reagents, consumables, equipment, calibration and maintenance services, including 30 from the Eastern China region, 16 from the Southern China region, 8 from the Northern China region, 50 from the Central China region and 1 from the Southwest and Northwest China region. In this Reporting Period, we also adopted a supplier assessment system and assessed 97 suppliers.

### 5. Anti-Corruption and Building Integrity

Kindstar Global has strictly complied with the Anti-Money Laundering Law of the People's Republic of China (《中 華人民共和國反洗錢法》), the Company Law of the People's Republic of China (《中華人民共和國公司法》) and other relevant regulations, and has formulated the Anti-Bribery Compliance Manual (《反賄賂合規手冊》). Our employees are not allowed to engage in any bribery activities in business activities. We require our employees to sign the Certificate of Compliance with Anti-Bribery Policy (《反賄賂政策合規證明》) to ensure that they thoroughly understand the Group's requirements for anti-bribery compliance operations. The Group's compliance officer strictly approves and monitors the reasonableness and compliance of all employees and collaborators in their operations.

We believe that quality is the foundation of our business and the rationale why companies want to work with us. We strive for cooperation opportunities with quality and will never use illegal methods to obtain cooperation with other units. All of our agents, distributors and sales representatives have signed cooperation contracts and are required to operate according to the contracts. We strictly prohibit any non-compliant commission payment activities. To ensure that the Group complies with the regulations, we invited independent auditors to conduct independent audits. We also conduct regular internal audits to ensure that all ledgers and financial records are complete and correct, to investigate the movement of large sums of money, to ensure that the operations with agents, distributors and sales representatives comply with the contractual requirements, and to ensure that the original contracts have not been amended unlawfully.

We have established a whistleblower system to encourage employees to report any violation of the Anti-Bribery Compliance Manual (《反賄賂合規手冊》). We provide hotline and email address in our Anti-Bribery Compliance Manual (《反賄賂合規手冊》) and Employee Handbook (《員工手冊》), and employees could also report to their supervisors, directors or compliance officers. We ensure no employee suffers negative consequences as a result of a whistleblowing action. Once an incident is confirmed, we will take serious action if any violation occurs, and disciplinary action will be taken according to the seriousness of the incident. If the incident is serious enough to violate criminal or civil laws, we will not tolerate and will report it to law enforcement agencies.



#### **Procedures of Reporting and Internal Investigation**

During the Reporting Period, we provided a total of 3,125 hours of "Anti-Corruption, Anti-Bribery, Anti-Corruption and Environmental Violations Training" to the Board and staff. The training is composed of four main parts, including anticorruption, anti-bribery, anti-corruption fraud and anti-environmental violations. Throughout the training, we explained the key points of the anti-corruption laws in China and Hong Kong, and also provided information on the preventive measures against corruption and fraud in procurement, personnel and administration, and accounting, such as spot-checking suppliers' quotations, checking payment applications for unusual amounts, etc.

We also explained the internal control principles of the Group's anti-corruption efforts in the training, including the establishment of unambiguous corporate policies, work procedures, terms of reference, and review of the monitoring system and regular independent audits. In our training on corporate environmental crimes, we pointed out that environmental crimes are mostly classified into destruction of resources, environmental pollution and illegal import and export of pollutants. We also pointed out some common management loopholes in companies, such as failure to comply with monitoring when cooperating with third parties, and failure to integrate compliance governance mechanism in internal management.

During the Reporting Period, there is no corruption case filed against us or our employees.

#### Establishing disciplinary codes

The Group has formulated the corresponding disciplinary code, which is available for reference in the corresponding situations:

- It is strictly prohibited to illegally accept or offer benefits, and avoid accepting or offering overly extravagant entertainment;
- Remind employees to pay attention to conflicts of interest and prevent the abuse of proprietary information and financial information of the Company;
- Any employee who wants to work part-time must apply to the Company in advance;
- Correctly use the consultation and communication system, and specify the channels for inquiries or complaints.

#### Strengthening regulatory system

The Group formulated ten regulatory principles for internal supervision to standardize employee behavior and strengthen internal supervision:

- Clear and specific company policies;
- Clear working procedures;
- Clearly-defined scope of responsibilities;
- Proper division of functions and responsibilities;
- Properly preserve sensitive information;
- Effectively implement regulatory measures;
- Conduct independent audit on a regular basis;
- Provide channels for complaints and advice;
- Continuously review the supervisory system;
- Do not tolerate any illegal behavior.

### 6. Human Resources Management

Employees are one of the key factors leading to the success of Kindstar Global. We focus on the Group's human resources and put forward the idea of being "People-Oriented" in our corporate development, providing our employees with compensation, vacation benefits, career development, employee activities, etc., to increase their sense of belonging to the Group and to retain important talents. As of December 31, 2023, the total number of employees in the Group was 3,125.

#### 6.1. Employee Recruitment System

The Group strictly abides by the requirements of the Labour Law of the People's Republic of China 《中華 人民共和國勞動法》, the Labour Contract Law (《勞動合同法》), the Labor Dispute Mediation and Arbitration Law of the People's Republic of China 《中華人民共和國勞動爭議調解仲裁法》), the Labor and Employment Promotion Law of the People's Republic of China 《中華人民共和國勞動就業促進法》), Employment Services and Employment Management Regulations (《就業服務和就業管理規定》), and the Prohibition of Child Labour (《禁止 使用童工》) and other regulations. We have formulated the Employee Handbook 《員工手冊》) and the Kindstar Global Human Resources Management System (《康聖環球人才資源管理制度》), which include recruitment and hiring, labour services, attendance management, personnel changes, training and development, compensation and benefits, and performance appraisal. The Group prohibits any kind of discrimination and establishes an equal and harmonious working environment for our employees.

We publish recruitment postings on different platforms according to job requirements. After screening of the candidates' resumes, we conduct assessments, written tests and interviews for the right candidates. When recruiting, we will ask candidates to provide personal information such as age, education and professional qualifications for reviewing and verifying. The Group strictly prohibits any cases of child labour. We will carefully check the personal information of the person to ensure that he/she has reached legal working age before hiring. If child labour has been found to have occurred, we will terminate the employment contract with the person immediately.

When signing an employment contract with a new employee, we will specify the contract period, probationary period and other relevant information. Employees have the right to resign and we have defined the procedures for employees to leave the Company. Employees are required to notify the Human Resources Department in advance before they leave the Group. Within the specified notice period, employees hand over the work and we calculate the wages of the departing employees and release the final payment of wages.

The Company's Employee Handbook (《員工手冊》) specified the working hours of employees, they are required to attend work according to the regulations to prevent any forced labour. The Group does not encourage the occurrence of overtime work. For overtime work, employees have to apply and seek approval from the Human Resources Department in advance, and the amount of overtime work is limited and must not be excessive. We prohibit any kinds of forced labor, and in the event of any non-compliance, we will take appropriate actions to rectify it.

During the Reporting Period, the Group did not violate any regulation on compensation and dismissal, recruitment and promotion, working hours, rest periods, equal opportunity, diversity, anti-discrimination and other benefits and welfare, as well as child labor or forced labor.

#### 6.2. Protection of Employee Benefits

To cater to the needs of our employees, we do not only provide the mandatory "five social insurances and one housing fund (i.e. pension insurance, work injury insurance, medical insurance, unemployment insurance, maternity insurance and housing fund)" to our employees, but also provide various leave benefits and allowances for our employees. The Group actively listens to the views and opinions of our employees and holds staff communication activities from time to time through different internal communication channels, such as corporate WeChat, company emails, staff services, opinion surveys, meetings, etc., to encourage staff to share their views and enhance communication among them.

We have established a compensation and benefits system for our employees. Employees are entitled to a legal basic salary and other allowances such as assessment salary, overtime salary, business commission, bonus, etc. We review our compensation system every year to provide our employees with a competitive compensation package. In terms of the welfare system, we provide subsidies such as transportation allowance, training fee reimbursement, annual employee bonus, etc. In terms of the vacation leave system, apart from the statutory leave entitlement, we also provide various leave benefits to our employees, such as wedding leave, maternity leave, personal leave, annual leave, etc. To strengthen the motivation of our employees for business, we have established a business commission and bonus system for our employees to drive business development of the Group.

In order to let our employees feel the corporate culture of Kindstar Global, we held many activities for employees to enhance the cohesion and unity of the Group. We celebrate specific holidays such as the Dragon Boat Festival, Christmas, Mid-Autumn Festival and employees' birthdays, etc. We prepared corresponding holiday gifts for employees and send them blessings.



Women's Day Activities



Dragon Boat Festival Make "Zongzi" Activities



Christmas Eve Activities

#### 6.3. Career Skills Development

The Group focuses on the career development of the employees. We provide development opportunities for our employees by providing them with various trainings, including skills and industry-related training, to enhance the competitiveness of Kindstar Global in the market. In the Reporting Period, we have maintained the Staff Position/Rank Promotion Management System (《員工崗位/職級晉級管理制度》), which clearly lists the promotion requirements for employees. Employees are required to reach the qualified promotion score in the previous year's performance appraisal and fulfill the points target set by the department before participating in employee promotion appraisal. According to the grade requirements, the supervisor, department head or career development committee will conduct the evaluation, and the qualified candidates for promotion will be subject to a probationary period, employee can become a full member after passing the assessment during the probationary period.

We provide on job training for our employees every year to drive their career development and keep them abreast of the latest technological developments. We have established learning courses such as "Kindstar Lexiang", "Kindstar College (Classroom)", "Kindstar Library (Knowledge Base)" and "Kindstar Zhihu (Questionand-Answer)". The training courses provide different training contents for specified employees, such as new employees training about the company's corporate culture and business processes, facilitating employees to understand and integrate into their work. We also develop a series of online and offline training courses for the development of employees' generic skills and management leadership. These courses help employees master various professional competencies and help to raise their awareness in transforming their roles so that they can be more competent for their positions. Training participation is an important basis for the evaluation of salary adjustment, career promotion and year-end merit. The Group actively promotes experienced and talented employees to become instructors in our training programs, providing a stage for the development of the employees.

We also encourage our employees to participate in external-training activities and programs. Employees can be reimbursed for related training expenses.



Staff Training Meetings

#### 6.4. Occupational Health and Safety

Kindstar Global complies with the Law of the People's Republic of China on Prevention and Control of Occupational Diseases (《中華人民共和國職業病防治法》), the Labor Protection Regulations for Female Employees (《女職工勞動保護規定》), and the Regulations on Supervision and Administration of Workplace Occupational Health (《工作場所職業衛生監督管規定》). We have developed a Safety Manual (《安全手冊》) to provide norms and guidelines for occupational safety management, detail safety-related management policies and procedures for handling emergency and hazardous situations have been listed in the Safety Manual.

For laboratory safety management, we have established a safety management team for the assessment and management of the environmental and testing safety of the laboratory. Laboratory staff is required to properly store hazardous chemicals and medical waste as required. Other staff are required to ensure that the working environment of the laboratory is clean and disinfected regularly. To ensure the biosafety management of the laboratory, we have established the biosafety management regulation, listing the details in the transportation, storage, and safekeeping of biological samples such as microorganisms and keeping records. These records must be kept by professional staff to prevent leakage. Daily management of the laboratory must be carried out according to the safety system established, and regular inspection, maintenance and updating of laboratory equipment, facilities and materials must be carried out to comply with national standards to ensure the health and safety of laboratory use.

Apart from the working environment, Kindstar Global is also concerned about the health condition of our employees, hoping that they will pay higher attention to their health condition. In the Reporting Period, we organized regular health checks or immunity screening tests for our employees. During the pandemic, we adjusted the commuting arrangements of our employees according to the epidemic prevention requirements of the locations and the situation of the Group. To ensure the safety of our employees, we have formulated a series of epidemic prevention policies, including the provision of masks to our employees, requirement of our employees to undergo regular nucleic acid or antigen testing, and conducting regular disinfection of workplaces. Including the Reporting Period and the past three years, the Group did not have any work-related fatalities records and the number of working days lost due to work-related injuries was 91. During the Reporting Period, the Group did not violate any laws and regulations relating to occupational health and safety.

In the Reporting Period, Wuhan Kindstar Medical Laboratory Co., Ltd successfully obtained 《GB/T 45001-2020/ISO 45001:2018 Occupational Health and Safety Management System Certification》, which is a recognition of our occupational safety management.



Wuhan Kindstar Medical Laboratory Co., Ltd obtained 《GB/T 45001-2020/ISO 45001:2018 Occupational Health and Safety Management System Certification》

### 7. Promoting Environmental Protection

Kindstar Global is highly concerned about its environmental impacts and strives to reduce the impact on the environment while driving our business development. We strictly comply with environmental laws and regulations, including the Law of the People's Republic of China on the Prevention and Control of Environmental Pollution by Solid Waste (《中華人民共和國固體廢物污染環境防治法》), the Biosecurity Law of the People's Republic of China (《中華人民 共和國生物安全法》), the Measures for Medical Wastes Management of Medical and Health Institutions (《醫療衛生機 構廢物管理辦法》), the Regulations on the Administration of Medical Wastes (《醫療廢物管理條例》), and the Regulation on the Bio-safety Management of Pathogenic Microbe Labs (《病原微生物實驗室生物安全管理條例》).

In the Reporting Period, the Group has set out directional environmental targets to progressively reduce or maintain greenhouse gas emissions and waste generation intensity and reduce energy consumption and water consumption intensity while maintaining operational levels. We will also set quantitative environmental targets and set environmental base years when appropriate.

During the Reporting Period, one of our testing laboratory, Wuhan Kindstar Medical Laboratory Co., Ltd successfully obtained the 《GB/T 24001-2016/ISO 14001:2015 Environmental Management System Certification》, which affirms our work on environmental management.



Wuhan Kindstar Medical Laboratory Co., Ltd obtained 《GB/T 24001-2016/ISO 14001:2015 Environmental Management System Certification》

#### 7.1. Combating Climate Change

Climate change is closely related to sustainable corporate development and the Group is concerned about the national "3060" goal of reaching the carbon peak and achieving carbon neutral targets. We have identified climate-related risks that may affect the Group, including physical and transition risks, analyzed the potential impacts of such risks on the Group and formulated corresponding mitigation measures. We will continue to optimize our climate risk management assessment and measures to reduce the impact on our business.

Risk Categories	Impact on the Group	Measures
Physical Risk		
Immediate risk: Extreme weather accidents	Natural disasters/extreme weather (heat waves, floods, hot weather, cold weather) may cause related emergencies (sample storage environment affected, transport chain interrupted, employee safety and work environment safety threatened).	The Group continues to pay attention to the relevant weather warnings issued by the Meteorological Bureau, and initiates the emergency plan management system when natural disasters break out and extreme weather occurs, and requires employees to take shelter in time. In summer with hot weather, the Group propagates the knowledge of heat prevention to employees and provides high temperature subsidies.
<b>Long-term risks:</b> Global temperatures rise, sea levels rise	Global warming leads to glacier melting, sea level rise and other chronic changes on the future production of products, product storage and transportation impact.	Continue to pay attention to the situation of global warming, improve the laboratory operating environment, sample transportation environment and staff working environment.
Transition Risk Policy and regulatory risks: Tightening of climate-related policies	Policies on energy conservation and emission reduction, stricter emission reporting obligations and compliance requirements.	Continue to monitor regulatory trends to ensure that the Group's emissions comply with the latest legal requirements.

Risk Categories	Impact on the Group	Measures
<b>Technical risks:</b> Products are replaced by new low-carbon technology products	The medical market expects products to be cleaner and more environmentally friendly, or the Group's products to be completely replaced by new technology products.	Continue to encourage research and development and innovation, pay attention to new market trends, pay attention to the emergence of new technology products, and widely attract talents.
Market risks: Increasing market demand for green products	The medical device market is paying more attention to green products, and the emergence of greener similar products has reduced the market competitiveness of the Group's products.	Continue to encourage research and development and innovation, explore green procurement paths, use green technology to produce green products, and maintain core competitiveness with a high level of technology and professional production capacity over the years.
<b>Reputational risk:</b> Society's impression and evaluation of low-carbon enterprises	Customers or communities have a poor impression and evaluation of high-carbon emission enterprises, so they do not invest in or buy their products, which affects their	Continue to implement measures to reduce carbon emissions, disclose and publicize the company's ESG contribution to the community, and call for carbon reduction actions.

profitability and market share.

#### 7.2. Green Operation Management

#### 7.2.1. Waste Management

As a clinical testing service provider, the treatment of medical waste is a vital part of the Group's environmental management system. Kindstar Global fulfills the compliance requirements for the disposal of medical waste and strictly controls the amount of waste generated. We have established the Medical Waste Temporary Storage Room Management System (《醫療廢物暫存間管理制》), which classifies medical waste into infectious, sharps, pathological, pharmaceutical and chemical waste. Each type of waste must be properly sealed, sorted, labeled and registered, and stored in an appropriate place before being collected and disposed of by third parties. Each waste disposal is required to be registered and recorded and kept for at least three years, registration information includes the type of waste, quantity, weight, date of handover, and the person in charge. If there is a large amount of expired pharmaceutical waste, we will return it to the manufacturer for disposal. Staff handling medical waste are required to take proper personal protection measures and disinfect the storage site after each disposal of medical waste to avoid waste residue causing secondary infection or contamination. We provide relevant safety and handling training for staff handling medical waste and monitor the entire medical waste handling process to comply with the Group's requirements.

During the year, the packaging materials used by the Group are paper, plastic and packaging bags. The main business of the Group does not involve the use of packaging materials. We will check the usage and reduce the waste of packaging materials in our products. For general household waste, we will sort the waste and recycle and treat various recyclable items. We also promote and encourage the reuse of resources, reduce the use of disposable items and avoid unnecessary waste.

During the year, the Group produced 153.40 tonnes (2022:760.05 tonnes) and 100.79 tonnes (2022:110.85 tonnes) of medical waste and non-hazardous waste, with an average medical waste and non-hazardous waste generation per employee of 0.05 tonnes (2022: 0.23 tonnes) and 0.03 tonnes (2022:0.03 tonnes). The significant decrease in medical waste produced by the Group compared to last year was mainly due to the technological update of the Group's testing business during the year, as well as a significant reduction in the nucleic acid testing business, which resulted in a corresponding decrease in medical waste such as testing consumables and tested samples.

#### 7.2.2. Water Resources Management

We cherish water resources and always remind our staff to use water efficiently to avoid wastage. The Group uses water supplied by the municipal government and has no problem in water sourcing. We affix water-saving labels next to each water-using equipment, use highly water-efficient equipment, and conduct inspections regularly on water-using equipment and water pipes to see if there are any leakages. During the year, the Group's water consumption was 20,273.20 tonnes (2022:31,350.68 tonnes) and the average water consumption per employee was 6.49 tonnes (2022:9.31 tonnes). The significant decrease in the Group's testing business during the year and the significant reduction in the nucleic acid testing business, which resulted in a corresponding decrease in the water consumption involved in the testing business.

The Group strictly controls the wastewater discharge. Our laboratories have obtained sewage discharge permit. All sewage discharged must first be treated by the Group's wastewater treatment facilities and have to comply with the discharge standard of Discharge Standard of Water Pollutants For Medical Organization (《醫療機構水污染物排放標準》) before discharging. We hire third-party environmental testing laboratories to test our effluent discharge every year to ensure that the concentration of pollutants complies with the standard. In the Reporting Period, the Group's wastewater discharge did not fail to meet the standard. In addition, office and daily sewage will be discharged to the municipal sewerage network after pre-treatment, and the treated effluent after pre-treatment meet the tertiary discharge standard of the Integrated Sewage Discharge Standard (《污水綜合排放標準》) and be treated by the local sewage treatment facilities centrally.

#### 7.2.3. Energy Use Management

We adhere to the code of energy saving to avoid unnecessary energy waste. For lighting and air conditioning systems, we use energy-efficient lighting fixtures and regularly clean the air conditioning filters to ensure that the systems are operating at their best condition. We have separated the operating area into different zones, each zone contains independent switch control; the air conditioning is managed by a central system to control the time and temperature of each zone to reduce energy waste. We will give higher preference to electric vehicles or hybrid vehicles and regularly conduct maintenance of the vehicles. We conduct monthly statistics on the Group's electricity consumption and look for high consumption or any abnormalities in electricity consumption, improvements will be made if required. During the year, the Group's electricity consumption was 6,684.03 MWh (2022:5,985.66 MWh) and the average electricity consumption per employee was 2.14 MWh (2022:1.78 MWh). The significant increase in the Group's electricity consumption compared to the previous year was mainly due to the corresponding increase in electricity consumption generated during the year by the Group's opening of new laboratories, expansion of some of its operating sites, renovation, etc.

#### 7.2.4. Greenhouse Gas ("GHG") Emissions Management

During the Reporting Period, the Group's GHG emissions were 4,160.55 tonnes  $CO_2e$  (2022:3,581.09 tonnes  $CO_2e$ ) and its average GHG emissions per employee were 1.33 tonnes  $CO_2e$  (2022:1.06 tonnes  $CO_2e$ ). Low carbon living has become a global trend, Kindstar Global has been encouraging employees to actively participate in low carbon-related activities e.g. adopting video business conferencing instead of business travel, using public transportation more often. We have promoted and educated our employees about environmental protection measures through various platforms, and encourage them to integrate environmental protection concepts into daily lives.

#### 7.2.5. Air Pollutants Emission Management

During the Reporting Period, the Group's emissions of NOx, SOx and particulate matter from company vehicles were 818.90 kg, 1.54 kg and 74.74 kg (2022:423.68 kg, 0.56 kg and 36.01 kg). The significant increase in the Group's air emissions compared to the previous year was mainly due to the increase in the Group's medical specimen transport business during the year and the corresponding increase in air emissions generated as a result of the increase in vehicle use.

To reduce emissions of NOx, SOx and particulate matter, we have adopted electric or hybrid vehicles, which are regularly maintained to ensure that they can operate with high efficiency and low emissions. The Group regularly monitors the air quality of the laboratories and has commissioned a third-party laboratories to test the VOCs emissions of the laboratories to comply with the regulatory emission standards. During the Reporting Period, the Group's laboratory air quality has complied with the standards.

### 8. Public Welfare and Harmonious Community

Kindstar Global has always been caring for the community and lends a helping hand to the public when needed. In 2023, Kindstar Global held the "Hand in Hand" June 1 event for children with blood diseases to extend care to the children and their families.



Kindstar Global actively organizes youth research activities, bringing young people closer to science and testing, experiencing the use of laboratory equipment, and promoting science education and health education.



# Appendix 1 : Sustainable development information summary

Environmental Category	Unit	2023	2022
Air pollutant emissions Nitric Oxides (NOx)	ka	818.90	423.68
Sulfur Oxides (SOx)	kg kg	1.54	423.08
Particulate Matter (PM)	kg	74.74	36.01
		14.14	00.01
Greenhouse gas emissions			
Direct GHG emissions (Scope 1)	carbon dioxide equivalent (tonnes)	277.45	103.42
Indirect GHG emissions (Scope 2)	carbon dioxide equivalent (tonnes)	3,883.10	3,477.67
Total GHG emissions	carbon dioxide equivalent (tonnes)	4,160.55	3,581.09
Intensity of GHG emissions (per square meter)	carbon dioxide equivalent (tonnes)/m <sup>2</sup>	0.07	0.07
GHG emissions (per employee)	carbon dioxide equivalent	1.33	1.06
	(tonnes)/employee		
Energy consumption			
Total electricity consumption	MWh	6,684.03	5,985.66
Intensity of electricity consumption	MWh/m <sup>2</sup>	0.11	0.11
(per square meter)			
Intensity of electricity consumption	MWh/employee	2.14	1.78
(per employee)			
Gasoline consumption	liter	97,469.74	35,351.03
Diesel consumption	liter	6,779.00	2,785.72
Water consumption			
Total water consumption	cubic meter	20,273.20	31,340.68
Water consumption intensity (per square meter)	cubic meter/m <sup>2</sup>	0.34	0.59
Water consumption (per employee)	cubic meter/employee	6.49	9.31
Paper consumption			
Total paper consumption	ka	12,755.68	12,165.00
Paper consumption (per employee)	kg/employee	4.08	3.61
			0.01
Waste production			
Medical waste produced	tonnes	153.40	760.05
Medical waste produced (per employee)	tonnes/employee	0.05	0.23
Non-hazardous waste produced	tonnes	100.79	110.85
Non-hazardous waste produced (per employee)	tonnes/employee	0.03	0.03

Social Category	Unit	2023	2022
Total employees	people	3,125	3,367
Female employees	people	2,092	2,249
Male employees	people	1,033	1,118
Non-management employees	people	2,065	2,021
Intermediate management employees	people	427	382
Senior management employees	people	66	46
Short-term/part-time employees	people	567	918
Employees aged below 30	people	1,036	1,261
Employees aged 30-50	people	1,812	1,854
Employees aged 50 or above	people	277	252
Employees from China	people	3,123	3,363
Employees from foreign	people	2	4
Employees turnover rate			
Total Employee turnover rate	%	32.86	30.62
Female employee	%	30.64	29.30
Male employee	%	37.37	33.27
Employees aged below 30	%	43.53	50.18
Employees aged 30-50	%	28.64	21.10
Employees aged 50 or above	%	20.58	18.09
Employees from China	%	32.82	30.66
Employees from overseas	%	100.00	0.00
Occupational health and safety			
Work-related fatalities for the last three years	people	0	0
(including the reporting year)			
Rate of work-related fatalities for the last three years	%	0.00	0.00
(including the reporting year)			
Lost days due to work injury	days	91.00	152.50

Social Category	Unit	2023	2022
Employee training			
Percentage of employees trained by gender			
Female employees	%	72.00	64.53
Male employees	%	65.00	35.47
Percentage of employees trained by employee category			
Non-management employees	%	64.00	15.54
Intermediate management employees	%	98.00	70.49
Senior management employees	%	87.00	12.36
Short-term/part-time employees	%	7.00	1.61
Average training hours completed per employee by gender			
Female employees	hours	39.13	14.06
Male employees	hours	31.26	22.07
Average training hours completed per employee by employe	9		
category	-		
Non-management employees	hours	41.00	2.59
Intermediate management employees	hours	56.62	19.65
Senior management employees	hours	52.63	31.78
Short-term/part-time employees	hours	1.14	44.54

### **Content Index**

The "comply or explain" provisions of the Environmental, Social and Governance Reporting Guide.

Subject Areas		Content	Chapter Index
A. Environmental Aspect A1 : Emissior	IS		
General Disclosure	A1	<ul> <li>Information on:</li> <li>(a) the policies; and</li> <li>(b) compliance with relevant laws and regulations that have a significant impact on the issuer</li> <li>relating to air and greenhouse gas emissions, discharges into water and land, and generation of hazardous and non-hazardous waste.</li> </ul>	Green Operation Management
KPIs	A1.1 A1.2	The types of emissions and respective emissions data. Direct and energy indirect greenhouse gas emissions and intensity.	Green Operation Management Greenhouse Gas Emissions management
	A1.3 A1.4 A1.5 A1.6	Total hazardous waste produced and intensity. Total non-hazardous waste produced and intensity. Description of emissions target(s) set and steps taken to achieve them. Description of how hazardous and non-hazardous wastes are handled, and a description of reduction target(s) set and steps taken to achieve them.	Waste Management Waste Management Green Operation Management Green Operation Management
Aspect A2 <sup>:</sup> Use of R General Disclosure	esources A2	Policies on the efficient use of resources, including energy,	Green Operation
KPIs	A2.1 A2.2	water and other raw materials. Direct and/or indirect energy consumption by type in total and intensity. Water consumption in total and intensity.	Management Energy Use Management Water Resources
	A2.3	Description of energy use efficiency target(s) set and steps taken to achieve them.	Management Water Resources Management
	A2.4	Description of whether there is any issue in sourcing water that is fit for purpose, water efficiency target(s) set and steps taken to achieve them.	Water Resources Management
	A2.5	Total packaging material used for finished products and with reference to per unit produced.	Waste Management

Subject Areas		Content	Chapter Index
Aspect A3 : The Envi	ronmental	and Natural Resources	
General Disclosure	A3	Policies on minimising the significant impacts on the environment and natural resources.	The business of the Group does
KPIs	A3.1	Description of the significant impacts of activities on the environment and natural resources and the actions taken to manage them.	not cause any significant impacts on the environment and natural resources.
Aspect A4 : Climate (	Change		
General Disclosure	A4	Policies on identification and mitigation of significant climate- related issues which have impacted, and those which may impact.	Combating Climate Change
KPIs	A4.1	Description of the significant climate-related issues which have impacted, and those which may impact, the issuer, and the actions taken to manage them.	Combating Climate Change
B. Social			
Aspect B1 : Employm	nent		
General Disclosure	B1	<ul> <li>Information on:</li> <li>(a) the policies; and</li> <li>(b) compliance with relevant laws and regulations that have a significant impact on the issuer</li> <li>relating to compensation and dismissal, recruitment and promotion, working hours, rest periods, equal opportunity, diversity, anti-discrimination, and other benefits and welfare.</li> </ul>	Human Resources Management
KPIs	B1.1	Total workforce by gender, employment type (for example, full- or part-time), age group and geographical region.	Human Resources Management
	B1.2	Employee turnover rate by gender, age group and geographical region.	Human Resources Management

Subject Areas		Content	Chapter Index
Aspect B2 : Health a	nd Safety		
General Disclosure	B2	<ul> <li>Information on:</li> <li>(a) the policies; and</li> <li>(b) compliance with relevant laws and regulations that have a significant impact on the issuer</li> <li>relating to providing a safe working environment and protecting employees from occupational hazards.</li> </ul>	Occupational Health and Safety
KPIs	B2.1	Number and rate of work-related fatalities occurred in each of the past three years including the reporting year.	Occupational Health and Safety
	B2.2 B2.3	Lost days due to work injury. Description of occupational health and safety measures adopted, and how they are implemented and monitored.	Occupational Health and Safety Occupational Health and Safety
Aspect B3 : Developr	ment and 1	Fraining	
General Disclosure	B3	Policies on improving employees' knowledge and skills for discharging duties at work. Description of training activities.	Career Skills Development
KPIs	B3.1	The percentage of employees trained by gender and employee category.	Career Skills Development
	B3.2	The average training hours completed per employee by gender and employee category.	Career Skills Development
Aspect B4 <sup>:</sup> Labour S	tandards		
General Disclosure	B4	<ul> <li>Information on:</li> <li>(a) the policies; and</li> <li>(b) compliance with relevant laws and regulations that have a significant impact on the issuer</li> <li>relating to preventing child and forced labour.</li> </ul>	Human Resources Management
KPIs	B4.1	Description of measures to review employment practices to avoid child and forced labour.	Human Resources Management
	B4.2	Description of steps taken to eliminate such practices when discovered.	Human Resources Management

Subject Areas		Content	Chapter Index
Aspect B5 : Supply C	hain Man	agement	
General Disclosure	B5	Policies on managing environmental and social risks of the	Standardize
		supply chain.	Procurement
			Management
KPIs	B5.1	Number of suppliers by geographical region.	Standardize
			Procurement
			Management
	B5.2	Description of practices relating to engaging suppliers, number	Standardize
		of suppliers where the practices are being implemented, and	Procurement
		how they are implemented and monitored.	Management
	B5.3	Description of practices used to identify environmental	Standardize
		and social risks along the supply chain, and how they are	Procurement
		implemented and monitored.	Management
	B5.4	Description of practices used to promote environmentally	Standardize
		preferable products and services when selecting suppliers,	Procurement
		and how they are implemented and monitored.	Management
Aspect B6 : Product	Responsil	bility	
General Disclosure	B6	Information on:	Strict Control on the
		(a) the policies; and	Quality of Test
		(b) compliance with relevant laws and regulations that have	
		a significant impact on the issuer	
		relating to health and safety, advertising, labelling and privacy	
		matters relating to products and services provided and	
		methods of redress.	
KPIs	B6.1	Percentage of total products sold or shipped subject to recalls	Strict Control on the
		for safety and health reasons.	Quality of Test
	B6.2	Number of products and service related complaints received	High Quality
		and how they are dealt with.	Customer Service
	B6.3	Description of practices relating to observing and protecting	Promoting
		intellectual property rights.	Scientific Research
			Development
	B6.4	Description of quality assurance process and recall	Quality of Service
		procedures.	and Testing
	B6.5	Description of consumer data protection and privacy policies,	Safeguarding
		and how they are implemented and monitored.	Information Security

Subject Areas		Content	Chapter Index
Aspect B7 : Anti-corr	ruption		
General Disclosure	B7	Information on:	Anti-Corruption and
		(a) the policies; and	Building Integrity
		(b) compliance with relevant laws and regulations that have	
		a significant impact on the issuer	
		relating to bribery, extortion, fraud and money laundering.	
KPIs	B7.1	Number of concluded legal cases regarding corrupt practices	Anti-Corruption and
		brought against the issuer or its employees during the	Building Integrity
		reporting period and the outcomes of the cases.	
	B7.2	Description of preventive measures and whistle-blowing	Anti-Corruption and
		procedures, and how they are implemented and monitored.	Building Integrity
	B7.3	Description of anti-corruption training provided to directors	Anti-Corruption and
		and staff.	Building Integrity
Aspect B8 : Commun	ity Invest	ment	
General Disclosure	B8	Policies on community engagement to understand the needs	Public Welfare
		of the communities where the issuer operates and to ensure	and Harmonious
		its activities take into consideration the communities' interests.	Community
KPIs	B8.1	Focus areas of contribution (e.g. education, environmental	Public Welfare
		concerns, labour needs, health, culture, sport).	and Harmonious
			Community
	B8.2	Resources contributed (e.g. money or time) to the focus area.	Public Welfare
			and Harmonious
			Community